Genalyte

About Genalyte

Genalyte, Inc. is a diagnostics and analytics company founded in 2007 by Dr. Cary Gunn. Dr. Gunn, who holds a Ph.D. in Electrical Engineering from Caltech and served nearly a decade in the U.S. Air Force, established the company with a vision to decentralize diagnostic testing. His background in applied physics and extensive experience in technology, including co-founding Luxtera, an optical solutions developer, laid the groundwork for Genalyte's core technology.

The company's business model centers on providing rapid, on-site diagnostic services directly to healthcare providers, such as clinics and physician offices. This approach aims to replace the traditional process of sending samples to external labs, which often involves delays. Genalyte makes money through cloud lab testing fees, with no upfront equipment cost to the doctors. The company has secured significant funding over the years, including a $50 million round in 2021 led by Verily, an Alphabet company, bringing its total raised capital to over $142 million across multiple rounds. A key milestone was the March 2020 acquisition of BaseHealth, a healthcare data analytics firm, to integrate advanced analytics with its diagnostic capabilities.

Genalyte's flagship product is the Maverick™ Diagnostic System, a platform that uses silicon photonics technology to perform numerous simultaneous tests on a small volume of blood. This system, which includes the Merlin Automated Lab, can deliver results for a wide range of tests—from autoimmune disease monitoring to infectious agent screening—in under 30 minutes. The platform is designed to be placed directly in a clinical setting, providing real-time, actionable results that integrate directly into a clinic's Electronic Medical Records (EMR) system via its proprietary CloudLab platform. This allows physicians to discuss results with patients during their visit, improving the speed and efficiency of care.